Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ("Conavi" or the "Company"), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO of Conavi Medical, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto on May 5-6, 2025.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has closed its previously announced, upsized equity offering for aggregate gross proceeds of $20 million (the “Offering”).

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering. The offering is of common shares of the Company (“Common Shares”) or pre-funded common share purchase warrants of the Company in lieu of Common Shares (“Pre-Funded Warrants” and, together with the Common Shares, the “Securities”) (the “Offering”).

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today the results of its annual general meeting of shareholders held virtually on March 31, 2025 (the “Meeting”), as well as the adoption of amendments to the Company’s Stock Option Plan.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to provide an update in respect of its previously announced public offering (the “Offering”). The Company expects that the Offering will now proceed as an offering of common shares of the Company (“Common Shares”) (or pre-funded common share purchase warrants (“Pre-Funded Warrants” and, together with the Common Shares, the “Securities”) of the Company in lieu of Common Shares). The number of Securities to be distributed, the price of each Security and the size of the Offering will be determined by negotiation between the Company and the Agent (as defined below) in the context of the market with final terms to be determined at the time of pricing.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its common shares have been approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market, with trading set to commence on March 6, 2025. The ticker symbol will remain CNVIF, and no action is needed by shareholders. Trading on the OTCQB is expected to complement the Company's existing listing on the TSX Venture Exchange.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, responded today to new intracoronary imaging guidelines by the American College of Cardiology, American Heart Association and other medical organizations. The guidelines apply to patients presenting with acute coronary syndrome (ACS) and undergoing a coronary intervention in the left main artery or complex lesions. Notably, the guidelines are rated Class 1A, indicating the highest level of evidence and strongest level of recommendation.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today reported financial results for the fiscal quarter ended December 31, 2024. These unaudited interim results are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedure, is pleased to announce that it has entered into a Corporate Development and Strategic services agreement with BND Projects Inc. (“BND”).

Read More

Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedure, announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with an offering of units of the Company (“Units”), with each Unit consisting of one common share and one common share purchase warrant (the “Offering”).

Read More

- U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026 - Evolving medical guidelines position next-generation Novasight system as new imaging standard in interventional cardiology - Multiple non-dilutive opportunities being pursued to fund growth

Read More

Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the publication of a detailed review of its collaboration with U.S.-based Minnetronix, a world leader in high-precision medical device manufacturing. Published in the industry journal, Medical Design & Development, the article was co-authored by Tom Looby, Conavi Medical’s CEO and Darcy Hart, Minnetronix Medical’s Director of Optical Products.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”) announced that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) pursuant to the terms of the Omnibus Equity Incentive Plan effective January 2nd, 2025. A total of 1,073,685 Stock Options have been awarded to directors, officers, employees and consultants of the Company. The Stock Options are exercisable at a price of $0.70 CAD per share (being the closing price of the Company’s shares on the TSXV on January 2, 2025) for a period of 10 years from the date of the grant.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today reported financial results for the fiscal year ended September 30, 2024. These results are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Chief Executive Officer, Thomas Looby, will present an update on the Company’s business at the MedInvest MedTech, AI & Digital Health Conference on Wednesday, December 11, 2024 at 3:35 p.m. Eastern Time in New York City.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that its exclusive licensing partner in China, East Ocean Medical (Hong Kong) Company Limited (“EOM”), has received approval by the China National Medical Products Administration (“NMPA”) for its coronary imaging system, which is based on Novasight Hybrid™ System intellectual property licensed to it by the Company via a June 2021 technology transfer and licensing agreement ("TTLA"). EOM is an affiliate of Grand Pharmaceutical Group Ltd., which is a Hong Kong-based company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices.

Read More

Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that the peer-reviewed Journal of the American College of Cardiology: Cardiovascular Interventions has published an article by Tufaro et al. which provides an overview of recent developments in hybrid intracoronary imaging and discusses its potential value in different clinical and research areas, such as percutaneous coronary intervention (“PCI”) guidance, vulnerable plaque detection, and the assessment of focal and systemic therapies targeting atherosclerosis.

Read More

CONAVI MEDICAL CORP. (TSXV: CNVI) (“CONAVI MEDICAL” or the “Company”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has engaged the services of ICP Securities Inc. (“ICP”) to provide automated market making services...

Read More